Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 6,136 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 6,136 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $30.03, for a total transaction of $184,264.08. Following the completion of the sale, the insider now owns 74,158 shares in the company, valued at $2,226,964.74. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.65, for a total transaction of $152,075.00.
• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total value of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.52, for a total value of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The stock was sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total transaction of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Stock Up 3.7 %

AKRO stock opened at $31.05 on Thursday. The company has a market capitalization of $2.15 billion, a P/E ratio of -9.70 and a beta of -0.25. Akero Therapeutics, Inc. has a 12 month low of $11.25 and a 12 month high of $37.00. The firm’s fifty day simple moving average is $27.11 and its 200-day simple moving average is $24.14. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.89 and a quick ratio of 24.89.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. As a group, equities research analysts forecast that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Hedge Funds Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. grew its holdings in Akero Therapeutics by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after acquiring an additional 1,030 shares during the period. Russell Investments Group Ltd. boosted its position in Akero Therapeutics by 2,366.0% in the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Akero Therapeutics by 15.6% during the 1st quarter. Principal Financial Group Inc. now owns 13,766 shares of the company’s stock worth $348,000 after purchasing an additional 1,858 shares during the period. Handelsbanken Fonder AB increased its holdings in shares of Akero Therapeutics by 12.4% during the 3rd quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock valued at $574,000 after purchasing an additional 2,200 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in shares of Akero Therapeutics by 24.4% during the 1st quarter. ProShare Advisors LLC now owns 15,001 shares of the company’s stock valued at $379,000 after purchasing an additional 2,945 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AKRO. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a report on Tuesday, September 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Thursday, June 20th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Akero Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $43.20.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.